

## HR 2917

### Opioid Crisis Accountability Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 22, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (May 23, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/2917>

## Sponsor

**Name:** Rep. Gabbard, Tulsi [D-HI-2]

**Party:** Democratic • **State:** HI • **Chamber:** House

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Khanna, Ro [D-CA-17]	D · CA		May 22, 2019

## Committee Activity

Committee	Chamber	Activity	Date
Education and Workforce Committee	House	Referred To	May 22, 2019
Energy and Commerce Committee	House	Referred to	May 23, 2019

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 S 1584	Identical bill	May 21, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## **Opioid Crisis Accountability Act of 2019**

This bill establishes a series of restrictions and requirements relating to opioid marketing and distribution practices.

Specifically, the bill prohibits (1) knowingly making false advertising or marketing claims regarding the addictive nature of opioids; (2) knowingly supplying communities with quantities of opioids that are not medically reasonable; or (3) failing to report distribution orders, or patterns of orders, while knowing that the orders are not being dispensed in a medically reasonable manner. Employees of opioid manufacturers and distributors are subject to civil penalties and imprisonment for violations; corporations and executives are subject to civil penalties. Manufacturers shall also lose their period of market exclusivity.

Additionally, the Department of Health and Human Services must assess a fee against each corporation that, between January 1, 1993, and the date of enactment of this bill, manufactured or distributed opioids, if such opioids were covered under a federal health program at least once during this period. Manufacturers that fail to pay the fee shall lose associated drug approval until the fee is paid in full.

The bill authorizes collected civil penalties and fees to be used for activities that address opioid misuse and abuse, including family and educational programs.

### **Actions Timeline**

---

- **May 23, 2019:** Referred to the Subcommittee on Health.
- **May 22, 2019:** Introduced in House
- **May 22, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.